Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting

Gary Bryant  |  July 6, 2016

On June 15, the ACR and partnering physician specialist groups passed an American Medical Association (AMA) resolution opposing the proposed Medicare Part B drug payment demonstration during the AMA House of Delegates (HOD) meeting held June 11–15 in Chicago. Part B Payment Demo Resolution The resolution, which the ACR supported with the American Society of…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AMA House of Delegates (HOD)American Medical Association (AMA)Centers for Medicare & Medicaid Services (CMS)Medicare Part Bproposal

Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2016

In a recent study, 100% of patients with rheumatoid arthritis (RA) on infliximab experienced a cross-reaction when switched to its biosimilar (CT-P13, infliximab-dyyb). Plus in a recent study, a treat-to-target strategy proved effective for treating RA with biological disease-modifying anti-rheumatic drugs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiologicsBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)infliximabinfliximab-dyybRheumatoid Arthritis (RA)

Biosimilars: Unanswered Questions

Susan Bernstein  |  July 5, 2016

Debate continues about how biosimilars that are emerging to treat rheumatic diseases will be named and monitored, said panelists at a recent meeting in Washington, D.C.—Biosimilars in the United States: Next Steps. Angus Worthing, MD, FACR, FACP, a member of the ACR’s Government Affairs Committee, shared rheumatologists’ concerns as these new therapies come to market….

Filed under:Biologics/DMARDsDrug Updates Tagged with:ACR Government Affairs CommitteeBiologics & Biosimilarsrheumatic diseases

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Michele B. Kaufman, PharmD, BCGP  |  June 22, 2016

The FDA is currently accepting comments on a draft guideline for osteoporosis treatments, which calls for more research into the long-term effects of drugs on bone quality. Also, the FDA has rejected an application for approval of Apadaz in its current form…

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain Syndromes Tagged with:Benzhydrocodone hydrochlorideChronic painFDAFood and Drug AdministrationGuidelinesOsteoporosispostmenopauseRegulation

The Pay Disparity: Rheumatologist Pay Is Up, but It’s Still a Lower-Paid Specialty

Richard Quinn  |  June 17, 2016

According to a new report, rheumatology remains one of the lowest-paid specialties in medicine—despite an average pay increase of 12% over the past year. And only 44% of rheumatologists would choose the field again. Anne Bass, MD, says administrative red tape and other factors contribute to the lack of satisfaction…

Filed under:Career DevelopmentProfessional Topics Tagged with:CareerCareer satisfactionjob satisfactionrheumatologistsSalary

Certolizumab Combo Helps Curb RA Damage

David Douglas  |  June 15, 2016

NEW YORK (Reuters Health)—Certolizumab pegol (Cimzia, UCB Pharma) in combination with methotrexate does better than methotrexate alone in certain patients with early rheumatoid arthritis (RA), according to one-year results from a new trial. As Dr. Paul Emery of the University of Leeds, UK, explains in an email to Reuters Health, “This study used a unique…

Filed under:Drug Updates Tagged with:Certolizumab Pegolcombination therapyDisease-modifying antirheumatic drugs (DMARDs)MethotrexateRheumatoid Arthritis (RA)

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Autoimmunecase reportClinicalDiagnosisGlomerulonephritisimmune complexpatient careRenalRheumatoid arthritisrheumatologyTNF-Alpha inhibitor

Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2016

Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPediatric Conditions Tagged with:ApprovalsBiologicsBiosimilarsclinical trialsdrugetanerceptFDAknee painOsteoarthritisPediatricplaquePsoriasisrheumatologySafety

Tips on Vaccinating Patients with Rheumatic Diseases

Thomas R. Collins  |  June 13, 2016

CHICAGO—In October of last year, a 52-year-old woman came to see Kevin Winthrop, MD, MPH, associate professor in infectious diseases, public health and preventive medicine at the Oregon Health & Sciences University. She had rheumatoid arthritis and was taking methotrexate and prednisone. She had had little change in her RA disease severity and was considering…

Filed under:ConditionsPractice Support Tagged with:2016 State-of-the-Art Clinical SymposiumFluherpes zosterpatient carepneumoniaRheumatic Diseaserheumatology

University of Alabama at Birmingham’s Division of Clinical Immunology & Rheumatology Recognized for Excellence

Gretchen Henkel  |  June 13, 2016

An interdisciplinary and collaborative environment is a critical factor for the advancement of basic science and clinical research in the academic environment, says William J. Koopman, MD, former director of the University of Alabama at Birmingham’s (UAB’s) Division of Clinical Immunology and Rheumatology. And in 1977, when he was being recruited by Division Director J….

Filed under:ConditionsPediatric ConditionsProfessional TopicsProfilesResearch Rheum Tagged with:CareerexcellenceImmunologyPediatricProfileResearchrheumatologyUniversity of Alabama at Birmingham

  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 77
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences